National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)
GM149252
米国
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)
GM127652
米国
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)
GM129539
米国
Simons Foundation
SF349247
米国
引用
ジャーナル: Nat Commun / 年: 2024 タイトル: Neurotransmitter-bound bestrophin channel structures reveal small molecule drug targeting sites for disease treatment. 著者: Aaron P Owji / Jingyun Dong / Alec Kittredge / Jiali Wang / Yu Zhang / Tingting Yang / 要旨: Best1 and Best2 are two members of the bestrophin family of anion channels critically involved in the prevention of retinal degeneration and maintenance of intraocular pressure, respectively. Here, ...Best1 and Best2 are two members of the bestrophin family of anion channels critically involved in the prevention of retinal degeneration and maintenance of intraocular pressure, respectively. Here, we solved glutamate- and γ-aminobutyric acid (GABA)-bound Best2 structures, which delineate an intracellular glutamate binding site and an extracellular GABA binding site on Best2, respectively, identified extracellular GABA as a permeable activator of Best2, and elucidated the co-regulation of Best2 by glutamate, GABA and glutamine synthetase in vivo. We further identified multiple small molecules as activators of the bestrophin channels. Extensive analyses were carried out for a potent activator, 4-aminobenzoic acid (PABA): PABA-bound Best1 and Best2 structures are solved and illustrate the same binding site as in GABA-bound Best2; PABA treatment rescues the functional deficiency of patient-derived Best1 mutations. Together, our results demonstrate the mechanism and potential of multiple small molecule candidates as clinically applicable drugs for bestrophin-associated diseases/conditions.